Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dunn

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Lancet (London, England)|April 27, 2016
HIV moments and pre-exposure prophylaxis--Authors' replyDavid T Dunn, Mitzy Gafos, Ellen White, et al.
Vaccine|June 24, 2023
Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trialsDavid T Dunn, Richard Gilson, Sheena McCormack, et al.
The Lancet. HIV|June 13, 2018
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agentsDavid T Dunn, David V Glidden, Oliver T Stirrup, et al.
BMC Medical Research Methodology|June 26, 2023
Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted eventsDavid T Dunn, Oliver T Stirrup, Sheena McCormack, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United KingdomHannah Green, Peter Tilston, Esther Fearnhill, et al.
The Lancet. HIV|October 2, 2019
Mosaic effectiveness: measuring the impact of novel PrEP methodsDavid V Glidden, Megha L Mehrotra, David T Dunn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2012
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysisDavid I Dolling, David T Dunn, Anna-Maria Geretti, et al.
The Journal of Infectious Diseases|August 2, 2013
Persistence of HIV-1 transmitted drug resistance mutationsHannah Castro, Deenan Pillay, Patricia Cane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 21, 2015
Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United KingdomJean L Mbisa, Esther Fearnhill, David T Dunn, et al.
The Pediatric Infectious Disease Journal|May 8, 2004
Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infectionDiana M Gibb, Trinh Duong, Veronica A Leclezio, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Lancet (London, England)|April 27, 2016
HIV moments and pre-exposure prophylaxis--Authors' replyDavid T Dunn, Mitzy Gafos, Ellen White, et al.
Vaccine|June 24, 2023
Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trialsDavid T Dunn, Richard Gilson, Sheena McCormack, et al.
The Lancet. HIV|June 13, 2018
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agentsDavid T Dunn, David V Glidden, Oliver T Stirrup, et al.
BMC Medical Research Methodology|June 26, 2023
Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted eventsDavid T Dunn, Oliver T Stirrup, Sheena McCormack, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United KingdomHannah Green, Peter Tilston, Esther Fearnhill, et al.
The Lancet. HIV|October 2, 2019
Mosaic effectiveness: measuring the impact of novel PrEP methodsDavid V Glidden, Megha L Mehrotra, David T Dunn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2012
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysisDavid I Dolling, David T Dunn, Anna-Maria Geretti, et al.
The Journal of Infectious Diseases|August 2, 2013
Persistence of HIV-1 transmitted drug resistance mutationsHannah Castro, Deenan Pillay, Patricia Cane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 21, 2015
Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United KingdomJean L Mbisa, Esther Fearnhill, David T Dunn, et al.
The Pediatric Infectious Disease Journal|May 8, 2004
Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infectionDiana M Gibb, Trinh Duong, Veronica A Leclezio, et al.
Pageof 8